Editing Post-traumatic stress disorder (section)

==== Antidepressants ====
[[Selective serotonin reuptake inhibitors]] (SSRIs) and [[serotonin–norepinephrine reuptake inhibitor]]s (SNRIs) may have some benefit for PTSD symptoms.<ref name=Hos2015/><ref name=Jeffreys-2012>{{cite journal |vauthors=Jeffreys M, Capehart B, Friedman MJ |title=Pharmacotherapy for posttraumatic stress disorder: review with clinical applications |journal=[[Journal of Rehabilitation Research and Development]] |volume=49 |issue=5 |pages=703–715 |date=2012 |pmid=23015581 |doi=10.1682/JRRD.2011.09.0183 |quote=While evidence-based, trauma-focused psychotherapy is the preferred treatment for PTSD, pharmacotherapy is also an important treatment option. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors and the selective serotonin-norepinephrine reuptake inhibitor venlafaxine. |doi-access=free}}</ref><ref>{{cite journal |vauthors=Williams T, Phillips NJ, Stein DJ, Ipser JC |title=Pharmacotherapy for post traumatic stress disorder (PTSD) |journal=[[Cochrane Library|The Cochrane Database of Systematic Reviews]] |volume=2022 |issue=3 |pages=CD002795 |date=March 2022 |pmid=35234292 |pmc=8889888 |doi=10.1002/14651858.CD002795.pub3 }}</ref> [[Tricyclic antidepressants]] are equally effective, but are less well tolerated.<ref>{{cite journal |vauthors=Puetz TW, Youngstedt SD, Herring MP |title=Effects of Pharmacotherapy on Combat-Related PTSD, Anxiety, and Depression: A Systematic Review and Meta-Regression Analysis |journal=[[PLOS ONE]] |volume=10 |issue=5 |pages=e0126529 |date=28 May 2015 |pmid=26020791 |pmc=4447407 |doi=10.1371/journal.pone.0126529 |veditors=Hashimoto K |quote=The cumulative evidence summarized in this review indicates that pharmacotherapy significantly reduces PTSD, anxiety, and depressive symptom severity among combat veterans with PTSD. The magnitude of the overall effects of pharmacotherapy on PTSD (Δ = 0.38), anxiety (Δ = 0.42), and depressive symptoms (Δ = 0.52) were moderate... |doi-access=free |bibcode=2015PLoSO..1026529P}}</ref> Evidence provides support for a small or modest improvement with [[sertraline]], [[fluoxetine]], [[paroxetine]], and [[venlafaxine]].<ref name=Hos2015/><ref>{{cite journal |vauthors=Kapfhammer HP |title=Patient-reported outcomes in post-traumatic stress disorder. Part II: focus on pharmacological treatment |language=en, es, fr |journal=[[Dialogues in Clinical Neuroscience]] |volume=16 |issue=2 |pages=227–237 |date=June 2014 |pmid=25152660 |pmc=4140515 |doi=10.31887/DCNS.2014.16.2/hkapfhammer}}</ref> Thus, these four medications are considered to be [[First-line treatment|first-line]] medications for PTSD.<ref name=Jeffreys-2012/><ref name="Berger-2009"/> The SSRIs paroxetine and sertraline are approved by the U.S. [[Food and Drug Administration]] (FDA) approved for the [[Treatments for PTSD|treatment of PTSD]].<ref name="Shalev 2017" />